Funding for this research was provided by:
Boehringer Ingelheim (N/A)
Received: 13 January 2022
Accepted: 29 April 2022
First Online: 21 May 2022
: The trial was carried out in accordance with the principles of the Declaration of Helsinki, the International Council for Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice, applicable regulatory requirements and Boehringer Ingelheim standard operating procedures.Written informed consent was obtained from all individual participants included in the study.
: Patients signed informed consent regarding publishing their data.
: Uwe Platzbecker received grant support, paid to GWT-TUD, from Amgen; lecture fees, grant support, paid to the University of Leipzig; fees for serving on a steering committee, consulting fees, and travel support from Celgene; grant support, paid to GWT-TUD, from Janssen Biotech; grant support, paid to University Dresden, from Merck and Novartis; and lecture fees from Novartis. Joerg Chromik declares no potential conflict of interest. Jan Krönke reports being part of an advisory council or committee for Janssen, Takeda, and Celgene/Bristol-Myers Squibb; received honoraria from Sanofi. Hiroshi Handa received honoraria from Janssen, Takeda, Celgene, Novartis, Ono, AbbVie, and Kyowa-Kirin; consulting fees from Janssen, Takeda, Celgene, and AbbVie; grants or funds from Takeda, Celgene, Novartis, Ono, AbbVie, Kyowa-Kirin, and Chugai. Stephen Strickland received consulting fees (in the past two years) from AbbVie, ArcherDx, Genentech, Incyte, Kura Oncology, Novartis, Pfizer, and Syros. Yasushi Miyazaki received honoraria from AbbVie, Novartis, Astellas, Synbio, Sumitomo-Dainippon, Chugai, Celgene, Nippon-shinyaku, Ohtsuka, and Kyouwa-Kirin; and grants or funds from Sumitomo-Dainippon, and Chugai. Martin Wermke received honoraria from Bristol-Myers Squibb, Merck, Roche, Novartis, Kite, Boehringer Ingelheim, and AstraZeneca; consulting or advisory role fees from Bristol-Myers Squibb, Novartis, Kite, Heidelberg Pharma, Roche, and Boehringer Ingelheim; travel, accommodation, expenses from Glenmark, Bristol-Myers Squibb, and AstraZeneca. Wataru Sakamoto is an employee of Nippon Boehringer Ingelheim Co., Ltd. Yoshifumi Tachibana is an employee of Nippon Boehringer Ingelheim. Tillmann Taube is an employee of Boehringer Ingelheim International. Ulrich Germing received speaker’s honorarium from Celgene, Novartis, and Jazz; consulting fees from Celgene; and institutional research support from Celgene, and Novartis.